

Table S5. Adverse Events

Summary of adverse events	Lower BCVA subgroup	Higher BCVA subgroup	Overall
	(n=170)	(n=31)	(N=201)
	n (%) E	n (%) E	n (%) E
Any AE	33 (19.4) 74	8 (25.8) 12	41 (20.4) 86
Any ocular AE in the study eye	24 (14.1) 32	3 (9.7) 3	27 (13.4) 35
Any non-ocular AE	13 (7.6) 18	4 (12.9) 6	17 (8.5) 24
Any SAE	3 (1.8) 4	1 (3.2) 3	4 (2.0) 7
Any ocular SAE in the study eye	0	0	0
Any non-ocular SAE	3 (1.8) 4	1 (3.2) 3	4 (2.0) 7
AE severity			
Mild	27 (15.9) 66	7 (22.6) 9	34 (16.9) 75
Moderate	6 (3.5) 8	0	6 (3.0) 8
Severe	0	1 (3.2) 3	1 (0.5) 3
AEs reported by ≥3 participants			
Cataract in study eye	5 (2.9) 5	0	5 (2.5) 5
Cataract subcapsular in study eye	5 (2.9) 5	0	5 (2.5) 5
Blepharitis in study eye	2 (1.2) 2	1 (3.2) 1	3 (1.5) 3
RP-related abnormalities in study eye	2 (1.2) 2	1 (3.2) 1	3 (1.5) 3
COVID-19	2 (1.2) 3	1 (3.2) 1	3 (1.5) 4

AE = adverse event; BCVA = best-corrected visual acuity; COVID-19 = coronavirus disease 2019; E = events; RP = retinitis pigmentosa; SAE = serious adverse event

Lower BCVA subgroup = 34–73 ETDRS letters

Higher BCVA subgroup = ≥74 ETDRS letters